-+ 0.00%
-+ 0.00%
-+ 0.00%

Citigroup Maintains Buy on Ligand Pharmaceuticals, Raises Price Target to $397

Benzinga·09/23/2026 15:13:41
Listen to the news
Citigroup analyst Yigal Nochomovitz maintains Ligand Pharmaceuticals (NASDAQ:LGND) with a Buy and raises the price target from $390 to $397.